Andreas Segerros

Président chez DEXTECH MEDICAL AB

Profil

Andreas Rutger Segerros is currently the Chief Executive Officer at Sylentis SA. He is also the Chairman at Oncorena AB, Dextech Medical AB, Oncorena Holding AB, and a Director at Prexton Therapeutics SA. Additionally, he is the Managing Partner at Eir Ventures Danmark ApS.
In his former positions, Mr. Segerros served as the Chief Executive Officer at Clinitrac AB and Nicox SA. He was also the Chairman at CMC Contrast AB and an Independent Director at Zyla Life Sciences LLC.
Furthermore, he held positions such as Director at Egalet Ltd., RSPR Pharma AB, Ferring Pharmaceuticals A, and Pharmacia, Inc. He was a Venture Partner at Sunstone Capital A from 2012 to 2019.
Mr. Segerros obtained an MBA from the University of Uppsala and completed his graduate studies at the Royal Institute of Technology.

Postes actifs de Andreas Segerros

Sociétés	Poste	Début
DEXTECH MEDICAL AB	Président	-
Oncorena Holding AB	Président	-
Oncorena AB	Président	-
Eir Ventures Danmark ApS	Private Equity Investor	01/07/2020
Prexton Therapeutics SA	Directeur/Membre du Conseil	-
Sylentis SA	Directeur Général	29/05/2024

Anciens postes connus de Andreas Segerros

Sociétés	Poste	Fin
NICOX SA	Directeur Général	28/02/2024
Sunstone Capital A/S	Private Equity Investor	01/02/2019
Ferring Pharmaceuticals A/S	Corporate Officer/Principal	-
░░░░░░░░░░ ░░░░	░░░░░░░░░ ░░░░░░░░░░░░░░░░░	-
░░░░ ░░░░ ░░░░░░░░	░░░░░░░░░░░░░░░░ ░░ ░░░░░░░	-

Formation de Andreas Segerros

University of Uppsala	Masters Business Admin
Royal Institute of Technology	Graduate Degree